Ricardo G. Teixeira was born on November 7 in the beautiful city of Lisbon. He completed his university studies at the University of Lisbon, where he obtained his Bachelor’s and Master’s degrees working with organometallic compounds. His Master’s thesis was focused on the development of ruthenium-based compounds as prospective anticancer agents and was supervised by Doctor Andreia Valente and Prof. Clara Viñas. During his Master’s, he also had the opportunity to enrich his professional (and cultural) experience during an internship at the Prof. Clara Viñas group at the Institute of Materials Science of Barcelona (ICMAB-CSIC, Spain) where he worked on the synthesis of new 3D carboranyl–ruthenium complexes as potential anticancer bimodal agents (chemo + radiotherapy). He has been a Ph.D. student in Inorganic Chemistry since 2019 at the Faculty of Sciences, University of Lisbon (Portugal) under the supervision of Doctor Andreia Valente and Doctor Ana Isabel Tomaz, developing new organometallic ruthenium-based drugs to fight multi-drug resistant cancers.
Ricardo G. Teixeira was born on November 7 in the beautiful city of Lisbon. He completed his university studies at the University of Lisbon, where he obtained his Bachelor’s and Master’s degrees working with organometallic compounds. His Master’s thesis was focused on the development of ruthenium-based compounds as prospective anticancer agents and was supervised by Doctor Andreia Valente and Prof. Clara Viñas. During his Master’s, he also had the opportunity to enrich his professional (and cultural) experience during an internship at the Prof. Clara Viñas group at the Institute of Materials Science of Barcelona (ICMAB-CSIC, Spain) where he worked on the synthesis of new 3D carboranyl–ruthenium complexes as potential anticancer bimodal agents (chemo + radiotherapy). He has been a Ph.D. student in Inorganic Chemistry since 2019 at the Faculty of Sciences, University of Lisbon (Portugal) under the supervision of Doctor Andreia Valente and Doctor Ana Isabel Tomaz, developing new organometallic ruthenium-based drugs to fight multi-drug resistant cancers.